Ekso Bionics Holdings, Inc.
Ekso Bionics Holdings, Inc. (EKSO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Ekso Bionics Holdings, Inc. (EKSO), covering cash flow, earnings, and balance sheets.
Ekso Bionics Holdings, Inc. (EKSO) Income Statement & Financial Overview
View the income breakdown for Ekso Bionics Holdings, Inc. EKSO across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.38M | $5.09M | $4.13M | $4.95M |
| Cost of Revenue | $1.57M | $2.38M | $1.92M | $2.31M |
| Gross Profit | $1.81M | $2.71M | $2.21M | $2.64M |
| Gross Profit Ratio | $0.54 | $0.53 | $0.53 | $0.53 |
| R&D Expenses | $988000.00 | $845000.00 | $777000.00 | $1.12M |
| SG&A Expenses | $4.26M | $4.10M | $4.07M | $3.86M |
| Operating Expenses | $5.25M | $4.94M | $4.85M | $4.97M |
| Total Costs & Expenses | $6.82M | $7.32M | $6.77M | $7.29M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$72000.00 | $59000.00 | $79000.00 | $74000.00 |
| Depreciation & Amortization | -$477000.00 | $398000.00 | $407000.00 | $397000.00 |
| EBITDA | -$3.44M | -$2.96M | -$1.59M | -$1.95M |
| EBITDA Ratio | -$1.02 | -$0.58 | -$0.38 | -$0.39 |
| Operating Income | -$3.44M | -$2.23M | -$2.64M | -$2.33M |
| Operating Income Ratio | -$1.02 | -$0.44 | -$0.64 | -$0.47 |
| Other Income/Expenses (Net) | $549000.00 | -$1.18M | $567000.00 | -$81000.00 |
| Income Before Tax | -$2.89M | -$3.41M | -$2.07M | -$2.42M |
| Income Before Tax Ratio | -$0.86 | -$0.67 | -$0.50 | -$0.49 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$2.89M | -$3.41M | -$2.07M | -$2.42M |
| Net Income Ratio | -$0.86 | -$0.67 | -$0.50 | -$0.49 |
| EPS | -$0.12 | -$0.17 | -$0.10 | -$0.13 |
| Diluted EPS | -$0.12 | -$0.17 | -$0.10 | -$0.13 |
| Weighted Avg Shares Outstanding | $25.39M | $24.64M | $20.31M | $18.22M |
| Weighted Avg Shares Outstanding (Diluted) | $25.39M | $24.64M | $20.31M | $18.22M |
Over the past four quarters, Ekso Bionics Holdings, Inc. demonstrated steady revenue growth, increasing from $4.95M in Q2 2024 to $3.38M in Q1 2025. Operating income reached -$3.44M in Q1 2025, maintaining a consistent -102% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$3.44M, reflecting operational efficiency. Net income rose to -$2.89M, with EPS at -$0.12. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan